Payment overview · 2025
General Payments
$317.51
7 reported records · 2 companies
Healthcare provider profile · identity verified
Kent Bin Cao, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1467536755
Verified facts
What the public records show
CMS Open Payments records show Kent Bin Cao, M.D. received $317.51 in general payments during 2025 across 7 reported records.
Gilead Sciences, Inc. accounted for 95.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Creon by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vemlidy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $302.29 | 95.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.22 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.51 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
83 | 26 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1566 | 310 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1228 | 264 |
| Amlodipine Besylate | Amlodipine Besylate | 1183 | 238 |
| Vascepa | Icosapent Ethyl | 743 | 118 |
| Raloxifene Hcl | Raloxifene Hcl | 699 | 127 |
| Metformin Hcl | Metformin Hcl | 690 | 116 |
| Omeprazole | Omeprazole | 601 | 154 |
| Tamsulosin Hcl | Tamsulosin Hcl | 469 | 95 |
| Glipizide Er | Glipizide | 400 | 64 |
| Simvastatin | Simvastatin | 393 | 79 |
| Finasteride | Finasteride | 385 | 76 |
| Alendronate Sodium | Alendronate Sodium | 384 | 83 |
| Donepezil Hcl | Donepezil Hcl | 362 | 64 |
| Famotidine | Famotidine | 359 | 73 |
| Azithromycin | Azithromycin | 357 | 232 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 337 | 55 |
| Carvedilol | Carvedilol | 303 | 45 |
| Diclofenac Epolamine | Diclofenac Epolamine | 303 | 95 |
| Diclofenac Sodium | Diclofenac Sodium | 295 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 266 | 97 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 260 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 259 | 53 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 240 | 46 |
| Mirtazapine | Mirtazapine | 216 | 46 |
| Hydrocortisone | Hydrocortisone | 203 | 86 |
| Montelukast Sodium | Montelukast Sodium | 202 | 39 |
| Atenolol | Atenolol | 181 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 34 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 155 | 26 |
| Ammonium Lactate | Ammonium Lactate | 146 | 65 |
| Eliquis | Apixaban | 141 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 45 |
| Xarelto | Rivaroxaban | 120 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 117 | 49 |
| Meclizine Hcl | Meclizine Hcl | 113 | 66 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 111 | 29 |
| Icosapent Ethyl | Icosapent Ethyl | 110 | 53 |
| Jardiance | Empagliflozin | 107 | 19 |
| Nifedipine Er | Nifedipine | 105 | 18 |
| Folic Acid | Folic Acid | 103 | 19 |
| Clotrimazole | Clotrimazole | 102 | 39 |
| Gabapentin | Gabapentin | 98 | 41 |
| Januvia | Sitagliptin Phosphate | 98 | 14 |
| Promethazine Hcl | Promethazine Hcl | 85 | 52 |
| Creon | Lipase/Protease/Amylase | 83 | 26 |
| Mupirocin | Mupirocin | 83 | 59 |
| Farxiga | Dapagliflozin Propanediol | 82 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 53 |
| Fenofibrate | Fenofibrate,micronized | 79 | 16 |
| Metformin Hcl Er | Metformin Hcl | 76 | 26 |
| Mometasone Furoate | Mometasone Furoate | 75 | 34 |
| Azelastine Hcl | Azelastine Hcl | 73 | 45 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 16 |
| Prednisone | Prednisone | 69 | 47 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 68 | 25 |
| Lisinopril | Lisinopril | 68 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 67 | 24 |
| Halobetasol Propionate | Halobetasol Propionate | 67 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 62 | 17 |
| Clonazepam | Clonazepam | 59 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 12 |
| Ibuprofen | Ibuprofen | 57 | 40 |
| Celecoxib | Celecoxib | 53 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 52 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 52 | 27 |
| Furosemide | Furosemide | 51 | 14 |
| Ketoconazole | Ketoconazole | 49 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 49 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Meloxicam | Meloxicam | 46 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 15 |
| Procto-Med Hc | Hydrocortisone | 44 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Ciclopirox | Ciclopirox | 39 | 11 |
| Amoxicillin | Amoxicillin | 37 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 21 |
| Bepotastine Besilate | Bepotastine Besilate | 36 | 18 |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Ursodiol | Ursodiol | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Prolia | Denosumab | 30 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Multaq | Dronedarone Hcl | 29 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 20 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 21 |
| Lidocaine | Lidocaine | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 17 |
| Diovan | Valsartan | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 15 |
| Brilinta | Ticagrelor | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nexium | Esomeprazole Magnesium | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Glipizide Xl | Glipizide | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 12 |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Flarex | Fluorometholone Acetate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 12 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.51 · 7 records | Gilead Sciences, Inc. | VYALEV | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error